The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Open accessPublished version of a preprint
Abstract
Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2mut detection. Experimental Design: Tumor tissue positive for HER2mut was required for eligibility. Neratinib was administered 240 mg daily with prophylactic loperamide. ctDNA sequencing was performed retrospectively for 54 patients (14 positive and 40 negative for tumor HER2mut). Results: Nine of 381 tumors (2.4%) sequenced centrally harbored HER2mut (lobular 7.8% vs. ductal 1.6%; P = 0.026). Thirteen additional HER2mut cases were identified locally. Twenty-one of these 22 HER2mut cases were estrogen receptor positive. Sixteen patients [median age 58 (31–74) years and three (2–10) prior metastatic regimens] received neratinib. The CBR was 31% [90% confidence interval (CI), 13%–55%], including one CR, one PR, and three SD ≥24 weeks. Median PFS was 16 (90% CI, 8–31) weeks. Diarrhea (grade 2, 44%; grade 3, 25%) was the most common adverse event. Baseline ctDNA sequencing identified the same HER2mut in 11 of 14 tumor-positive cases (sensitivity, 79%; 90% CI, 53%–94%) and correctly assigned 32 of 32 informative negative cases (specificity, 100%; 90% CI, 91%–100%). In addition, ctDNA HER2mut variant allele frequency decreased in nine of 11 paired samples at week 4, followed by an increase upon progression. Conclusions: Neratinib is active in HER2mut, nonamplified MBC. ctDNA sequencing offers a noninvasive strategy to identify patients with HER2mut cancers for clinical trial participation. Clin Cancer Res; 23(19); 5687–95. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Not only does it competitively occupy the ATP-binding site on EGFR, but it also binds to the unique amino acid residue Cys805 near the opening of the pocket-a homologous cysteine residue to EGFR Cys797-to undergo alkylation or covalent bonding, thus achieving irreversible inhibition of HER2.154,155”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
Self-citation
Cited by
Sorted by citations
Items 101–193 of 193
Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
Eli, L. D., & Kavuri, S. M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.48 · Cited by 17
Toss, A., Piacentini, F., Cortesi, L., Artuso, L., Bernardis, I., Parenti, S., Tenedini, E., Ficarra, G., Maiorana, A., Iannone, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25810 · Cited by 17
Fiste, O., Liontos, M., Koutsoukos, K., Terpos, E., Dimopoulos, M. A., & Zagouri, F. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1175 · Cited by 16
Towards Circulating-Tumor DNA-Based Precision Medicine
Hironaka‐Mitsuhashi, A., Calle, A. S., Ochiya, T., Takayama, S., & Suto, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091365 · Cited by 16
Clinical application of circulating tumor DNA in breast cancer
Chan, J. C. H., Chow, J. C. H., Ho, C. H. M., Tsui, T. Y. M., & Cho, W. C. S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03588-5 · Cited by 20
Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
Gautam, S. K., Kanchan, R. K., Siddiqui, J. A., Maurya, S. K., Rauth, S., Perumal, N., Atri, P., Venkata, R. C., Mallya, K. B., Mirza, S., et al. (2020) · Cancers · doi:10.3390/cancers12102838 · Cited by 15
Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing
Ranghiero, A., Frascarelli, C., Cursano, G., Pescia, C., Ivanova, M. D., Vacirca, D., Rappa, A., Taormina, S. V., Barberis, M. C. P., Fusco, N., et al. (2023) · Cytopathology · doi:10.1111/cyt.13295 · Cited by 17
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine
Afzal, M. Z., & Vahdat, L. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070719 · Cited by 17
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C., & Cristofanilli, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0667-9 · Cited by 16
Fan, K., Wang, J., Shen, S., Ni, X., Gong, Z., Zheng, B., Sun, W., Suo, T., Liu, H., Ni, X., et al. (2022) · Medical Oncology · doi:10.1007/s12032-021-01568-w · Cited by 14
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Cabel, L., Fuerea, A. C., Lacroix, L., Baldini, C., Martin, P., Hollebecque, A., Postel-Vinay, S. C., Varga, A., Balheda, R., Gazzah, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24188 · Cited by 14
High Frequency of Juxtamembrane DomainERBB2Mutation in Gastric Cancer
Park, S., Ahn, S., Kim, D. G., Kim, H., Kang, S. Y., & Kim, K. (2021) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20307 · Cited by 14
Novel technologies in cfDNA analysis and potential utility in clinic
Li, J., Xu, M., Peng, J., Wang, J., Zhao, Y., Wu, W., & Lan, X. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.06.07 · Cited by 15
Jongbloed, E. M., Deger, T., Sleijfer, S., Martens, J. W. M., Jager, A., & Wilting, S. M. (2021) · Cancers · doi:10.3390/cancers13081811 · Cited by 13
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features
Ding, Q., Chen, H., Lim, B., Damodaran, S., Chen, W., Tripathy, D., Piha-Paul, S. A., Luthra, R., Meric‐Bernstam, F., & Şahin, A. A. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.07.006 · Cited by 13
Self-citationSilver Jubilee of HER2 targeting: a clinical success in breast cancer
Zhao, J., Zhou, Z., Saw, P. E., & Song, E. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.12.008 · Cited by 16
Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice
Tao, G., Dagher, F., & Ghose, R. (2021) · Toxicology Research · doi:10.1093/toxres/tfab111 · Cited by 12
Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer
Kwon, M. J. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01402-5 · Cited by 12
Aguilar‐Mahecha, A., Lafleur, J., Brousse, S., Savichtcheva, O., Holden, K. A., Faulkner, N., McLennan, G., Jensen, T. J., & Basik, M. (2021) · Cancers · doi:10.3390/cancers13061331 · Cited by 13
Curado, M., Caramelo, A., Eloy, C., & Polónia, A. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02567-z · Cited by 11
Brogna, M. R., Ferrara, G., Varone, V., Montone, A., Fava, A. S., Schiano, M. R., Sesto, M. D., Pizza, N., Prota, A., Barra, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1642521 · Cited by 10
Grammoustianou, Μ., Dimitrakopoulos, F.-I. D., & Koutras, A. K. (2024) · Cancers · doi:10.3390/cancers16101801 · Cited by 13
Advances in liquid biopsy in neuroblastoma
Zhuo, Z., Lin, L., Miao, L., Li, M., & He, J. (2022) · Fundamental Research · doi:10.1016/j.fmre.2022.08.005 · Cited by 11
Uchida, S., Kojima, T., & Sugino, T. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.633243 · Cited by 10
Lin, R., Peng, B., Li, L., He, X., Yan, H., Tian, C., Luo, H., & Yin, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1258436 · Cited by 9
Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer
Kratz, J. D., Burkard, M. E., O’Meara, T. A., Pusztai, L., Veitch, Z. W. N., & Bedard, P. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200731 · Cited by 9
Self-citationInvestigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer
Gombos, A., Franzoi, M. A., & Awada, A. H. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1633306 · Cited by 8
Yuan, Y., Lee, J. S., Yost, S. E., Stiller, T., Blanchard, M. S., Padam, S., Katheria, V., Kim, H., Sun, C., Tang, A., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.020 · Cited by 9
Molecular Mechanisms of Endocrine Resistance
Fu, X., Angelis, C. D., Veeraraghavan, J., Osborne, C. K., & Schiff, R. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-99350-8_11 · Cited by 8
Sexual abuse and obesity: implications for the treatment of obesity.
King, T. K. (1997) · PubMed · Cited by 8
Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
Hejjioui, B. E., Bouguenouch, L., Melhouf, M. A., Mouhi, H. E., & Bennis, S. (2023) · Diagnostics · doi:10.3390/diagnostics13030470 · Cited by 7
Tian, H., Qu, M., Zhang, G., Yuan, L., Shi, Q., Wang, Y., Yang, Y., Zhang, Y., & Qi, X. (2023) · The Oncologist · doi:10.1093/oncolo/oyad122 · Cited by 7
Lei, L., Ye, W.-W., Zheng, L., Huang, P., Shi, L., Huang, J. H., Zheng, Y., Chen, Z., Wang, X., & Wang, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s199931 · Cited by 7
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Grill, S., & Klein, E. (2021) · Breast Care · doi:10.1159/000513800 · Cited by 7
Exman, P., Garrido-Castro, A. C., Hughes, M. E., Freedman, R. A., Li, T., Trippa, L., Bychkovsky, B., Barroso‐Sousa, R., Lascio, S. D., MacKichan, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00087 · Cited by 7
Self-citationKontogiannis, A., Karaviti, E., Karaviti, D., Lanitis, S., Gomatou, G., Syrigos, N. K., & Kotteas, E. A. (2024) · Cancers · doi:10.3390/cancers16223826 · Cited by 6
Genomic landscape of circulating tumour DNA in metastatic extramammary Paget’s disease
Sawamura, S., Myangat, T. M., Kajihara, I., Tanaka, K., Ide, M., Sakamoto, R., Otsuka‐Maeda, S., Kanemaru, H., Nishimura, Y., Yamada‐Kanazawa, S., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14476 · Cited by 6
Velaga, R., Tanaka, S., & Toi, M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.10 · Cited by 6
Mu, Y., Meng, Y., Du, Y., Liu, X., & Zhang, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15130 · Cited by 5
Jin, S., Sun, X., Liu, D., Xie, H., & Rao, Y. (2019) · Chemical Papers · doi:10.1007/s11696-019-00686-0 · Cited by 6
Yang, Z., Liu, Y., Xu, C., Wang, X., & Lei, L. (2020) · Biology Open · doi:10.1242/bio.047662 · Cited by 6
Mortimer, J. E., Kruper, L. L., Cianfrocca, M. E., Lavasani, S. M., Liu, S., Patel, N. H., Sedrak, M. S., Smith, W., Stewart, D. B., Waisman, J. R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061984 · Cited by 6
Wang, H., He, Y., Zhao, W., & Tong, Z. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001369 · Cited by 7
Annaratone, L., Sarotto, I., & Marchiò, C. (2018) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_4710-1 · Cited by 7
Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach
Shoukat, I., & Mueller, C. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2173579 · Cited by 5
Yayli, G., Tokofsky, A., & Nayar, U. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461190 · Cited by 5
Ma, J., Li, X., Zhang, Q., Li, N., Sun, S., Zhao, S., Zhao, Z., & Li, M. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101444 · Cited by 5
Detecting and Quantitating Low Fraction DNA Variants with Low-Depth SequencingPreprint
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.26.061747 · Cited by 5
Chow, C. Y. C., Lie, E. F., Wu, C., & Chow, L. W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.964824 · Cited by 4
Yeo, M., Kim, S., Yoo, H. J., Suh, K., & Kim, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236963 · Cited by 4
Pastò, B., Vida, R., Dri, A., Foffano, L., Rossa, S. D., Gerratana, L., & Puglisi, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103859 · Cited by 4
Paplomata, E., Zelnak, A. B., Santa-Maria, C. A., Liu, Y., Gogineni, K., Li, X., Moreno, C. S., Chen, Z., Kaklamani, V., & O'Regan, R. M. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.017 · Cited by 4
Shang, Y., Mo, J., Huo, R., Li, X., Fang, G., Wei, Z., Gu, G., Zhu, X., Zhang, C., Liu, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1064598 · Cited by 4
Nicolò, E., Munoz-Arcos, L. S., Vagia, E., D’Amico, P., Reduzzi, C., Donahue, J., Lorico-Rappa, M., Manai, M., Behdad, A., Zhang, Y., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00702 · Cited by 4
Bello, O., Rieur, O., & Vidula, N. (2026) · Pharmacogenomics · doi:10.1080/14622416.2026.2658438 · Cited by 3
Igari, F., Tanaka, H., & Giuliano, A. E. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103725 · Cited by 3
HER2 gene mutations and matrix biomarkers in breast cancer
Karimova, L., Azizova, G., & Shahverdiyeva, I. J. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.111007 · Cited by 3
Clinical implications of breast cancer tumor genomic testing
Damodaran, S., Sember, Q., & Arun, B. (2020) · The Breast Journal · doi:10.1111/tbj.13966 · Cited by 3
Prädiktive Mutationsdiagnostik bei Mammakarzinomen
Kreipe, H. H., & Sinn, H. (2021) · Der Pathologe · doi:10.1007/s00292-021-00929-6 · Cited by 3
Lenoue-Newton, M. L., Chen, S., Stricker, T., Hyman, D. M., Blauvelt, N., Bedard, P. L., Meric‐Bernstam, F., Punglia, R. S., Schrag, D., Lepisto, E. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0885 · Cited by 3
Self-citationHeeke, A. L., Elliott, A., O'Keefe, K., Livasy, C., Symanowski, J. T., Steiner, M. R., Kang, I. M., Hoon, D. S. �., Walker, P., Sledge, G. W., et al. (2025) · JCO Precision Oncology · doi:10.1200/po.23.00719 · Cited by 4
Egebjerg, K., Spanggaard, I., Ahlborn, L. B., Rohrberg, K. S., Harsløf, L. B. S., Hoejgaard, M., Schmidt, A. Y., Lassen, U., Tuxen, I. V., Hasselby, J. P., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14599-7 · Cited by 2
HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer
Murray, E. M., Cherian, M. A., Ma, C. X., & Bose, R. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0265-z · Cited by 2
Self-citationPlace des CTC et de l’ADN circulant dans la prise en charge du cancer du sein
Allouchery, V., Augusto, L., & Clatot, F. (2019) · ONCOLOGIE · doi:10.3166/onco-2019-0035 · Cited by 2
Marín, A., Mamun, A. A., Akamatsu, H., Ye, D., Sudhan, D. R., Brown, B. P., Eli, L. D., Marcelain, K., Meiler, J., Arteaga, C. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.23.509246 · Cited by 2
Li, S., Primeau, T. M., Highkin, M. K., Pratt, S. L., Tipton, A. R., Vemalapally, N., Monsey, J. D., Tao, Y., Luo, J. R., Hagemann, I. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.19.572069 · Cited by 3
Self-citationA comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer
Wang, Y., Gan, J., Hu, H., Xu, M., Xu, Y., Zhao, Y., Dong, W., Li, X., Zhu, H., Wang, S., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05550-3 · Cited by 2
Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer
de Azevedo, J. C., da Silva, F. J., Rodrigues, A. S., de Sousa, S. B. M., da Silva, J. M. C., Ramos, I. B., Borges, B. D. N., Freitas, V. M., & Calcagno, D. Q. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00800-x · Cited by 3
Place des biopsies liquides dans le diagnostic et la caractérisation moléculaire des cancers du sein
Vion, R., Fontanilles, M., Fiore, F. D., & Clatot, F. (2021) · Bulletin du Cancer · doi:10.1016/s0007-4551(21)00636-6 · Cited by 1
Personalisierte Medizin – innovative Therapiemöglichkeiten für das metastasierte Mammakarzinom
Dannehl, D., & Hartkopf, A. D. (2022) · Der Gynäkologe · doi:10.1007/s00129-022-04934-5 · Cited by 1
Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine
Foong, S., Simpson, P. T., Cummings, M. C., & Lakhani, S. R. (2022) · Springer eBooks · doi:10.1007/978-3-031-05532-4_23 · Cited by 1
Kərimova, L. Ə., Əzizova, G. İ., & Şahverdiyeva, İ. C. (2025) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2025.3.05 · Cited by 1
Neratinib-Induced Duodenal Ulcer: A Case Report
Moftakhar, B., Kharel, P., Niraula, S., Gandhi, S., Falkson, C. I., & Dhakal, A. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420935871 · Cited by 1
Sudhan, D. R., Zotano, Á. G., Won, H. H., Ericsson, P. I. G., Servetto, A., Lee, K., Formisano, L., Guo, Y. P., Liu, Q., Kinch, L. N., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3362256 · Cited by 1
Self-citationAnnaratone, L., Sarotto, I., & Marchiò, C. (2019) · Encyclopedia of pathology · doi:10.1007/978-3-319-62539-3_4710 · Cited by 1
Zhang, R., Gao, P., Ding, J., Li, Z., & Li, J. (2019) · Breast Cancer · doi:10.1007/s12282-019-01000-2
Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig?
Schmidt, M. (2020) · Journal für Gynäkologische Endokrinologie/Österreich · doi:10.1007/s41974-020-00141-z
Agnostische Tumortherapie – was ist das?
Schmidt, M., Hönig, A., Denkert, C., & Desuki, A. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04788-3
Boxberg, M., Grill, S., & Poremba, C. (2022) · Trillium Diagnostik · doi:10.47184/td.2022.01.05
Cheng, X., Sun, Y., Highkin, M. K., Vemalapally, N., Jin, X., Zhou, B., Prior, J. L., Tipton, A. R., Li, S., Iliuk, A. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.09.515796
Self-citationMolekularpathologie in der Gynäkoonkologie – Beschreibung einer Revolution
Ettl, J., & Kiechle, M. B. (2023) · Die Gynäkologie · doi:10.1007/s00129-023-05053-5
Personalisierte Medizin – von der Translation zur Klinik
Schmidt, M., Denkert, C., Rhiem, K., Decker, T. W., & Loibl, S. (2023) · Die Gynäkologie · doi:10.1007/s00129-023-05081-1
Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer
Gerratana, L., Reduzzi, C., D’Amico, P., Mazzeo, R., Jacob, S. L., Qiang, W., & Cristofanilli, M. (2023) · Current cancer research · doi:10.1007/978-3-031-22903-9_21
Personalisierte Medizin – von der Translation zur Klinik
Schmidt, M., Denkert, C., Rhiem, K., Decker, T. W., & Loibl, S. (2023) · Wiener klinisches Magazin · doi:10.1007/s00740-023-00502-2
The uncharted role of HER2 mutant alleles in breast cancer
Kalra, R., Lim, B., Ellis, M. J., & Kavuri, S. M. (2023) · Oncotarget · doi:10.18632/oncotarget.28489
Self-citationCheng, X., Hsia, J., Iraheta, J., Gongora, J. M., Highkin, M. K., Jin, X., Guo, Z., Prior, J. L., Edwards, J. R., Li, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.06.663368
Self-citationGene Mutation Classification in Cancer
de Melo, P. (2025) · Cancer Research Journal · doi:10.11648/j.crj.20251303.14
Darrigues, L., Pierga, J., Bernard-Tessier, A., Bièche, I., Silveira, A. B., Michel, M., Loirat, D., Cottu, P. H., Cabel, L., Dubot, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14175962
de Gruil, N., de Groot, A. F., Wesseling-Rozendaal, Y. J. W., Keizer, D., Koekenbier, C. S., Vermeer, S., Cohen, D., Heijns, J., Mandigers, C. M. P. W., van de Wouw, A. J., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02245-4
Lyu, Z., Han, W., Li, H., Liang, X., Su, X., & Wu, H. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101087
Elhabal, S. F., Morsy, S. A. A., Azer, M. S., Allam, K. M., Hassan, F. E., Ewedah, T. M., GALIL, R. M. A. E., El-Din, M. N., Ashmawy, A. I., Ahmed, H. S., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101244
Prognostic Markers in Triple-Negative Breast Cancer (TNBC)
Shah, I., Naik, S., Arfuso, F., Warrier, S. R., Dharmarajan, A., & Manohar, S. M. (2026) · Cancers · doi:10.3390/cancers18193181
HER2 mutation in metastatic breast cancer
ma, F. (2020) · China National GeneBank DataBase · doi:10.26036/cnp0001305
Metadata
- Authors
- Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., Winer, E., Naughton, M., Goetz, M. P., Russell, C., Tripathy, D., Cobleigh, M., Forero, A., Pluard, T. J., Anders, C., Niravath, P. A., Thomas, S., Anderson, J., Bumb, C., Banks, K. C., Lanman, R. B., Bryce, R., Lalani, A. S., Pfeifer, J., Hayes, D. F., Pegram, M., Blackwell, K., Bedard, P. L., Al-Kateb, H., & Ellis, M. J. C.
- Affiliations
- Washington University in St. Louis (US)
- Dana-Farber Cancer Institute (US)
- Stanford Medicine (US)
- Duke University (US)
- Mayo Clinic (US)
- University of Southern California (US)
- Rush University Medical Center (US)
- University of Alabama at Birmingham (US)
- Saint Luke's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Baylor College of Medicine (US)
- Guardant (United States) (US)
- Puma Biotechnology (United States) (US)
- University of Michigan (US)
- Princess Margaret Cancer Centre (CA)
- 15Genomic and Pathology Service, Washington University School of Medicine, St. Louis, Missouri.
- ORCID
- Ma, Cynthia X.
- Bose, Ron
- Gao, Feng
- Freedman, Rachel A.
- Telli, Melinda L.
- Kimmick, Gretchen
- Winer, Eric
- Goetz, Matthew P.
- Russell, Christy
- Tripathy, Debu
- Cobleigh, Melody
- Forero, Andres
- Pluard, Timothy J.
- Anders, Carey
- Niravath, Polly Ann
- Thomas, Shana
- Banks, Kimberly C.
- Lanman, Richard B.
- Bryce, Richard
- Lalani, Alshad S.
- Pfeifer, John
- Hayes, Daniel F.
- Pegram, Mark
- Blackwell, Kimberly
- Bedard, Philippe L.
- Ellis, Matthew J.C.
- Venue
- Clinical Cancer Research
- Published
- 2017-10-01
- Volume
- 23
- Issue
- 19
- Pages
- 5687-5695
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC6746403
- OpenAlex
- W2726739357
- Cited by
- 193
- References
- 49
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 6 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 3
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Puma Biotechnology
- National Cancer Institute (P30CA091842, P30CA016086)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- neratinib, HER2 mutation, circulating tumor DNA, liquid biopsy, clinical benefit rate, progression-free survival, diarrhea, HER2-positive breast cancer, lobular breast cancer, estrogen receptor-positive breast cancer, patient selection for clinical trials, targeted therapy
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Metastasis, Quinolines, Treatment Outcome, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
